Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

Vis graf over relationer
Although the reasons for secondary loss of response to infliximab (IFX) maintenance therapy in Crohn's disease vary, dose intensification is usually recommended. This study investigated the cost-effectiveness of interventions defined by an algorithm designed to identify specific reasons for therapeutic failure.
OriginalsprogEngelsk
TidsskriftGut
Vol/bind4
Udgave nummer63
Sider (fra-til)919
Antal sider9
ISSN0017-5749
DOI
StatusUdgivet - 2014

ID: 42508094